论文部分内容阅读
目的探讨卡培他滨与表柔比星在多西紫杉醇一线治疗转移性乳腺癌的效果。方法将60例转移性乳腺癌患者随机等分为卡培他滨组和表柔比星组,两组均给予多西紫杉醇一线治疗(75mg/m2静滴,第1d),并分别给予卡培他滨(每天2 000 mg/m2,分两次口服,第1～14d)和表柔比星(75mg/m2,静脉推注,第1d),21d为1个周期。分析两组的近期疗效(总有效率RR、疾病缓解率DCR),远期疗效(中位无进展生存期PFS)及治疗期间的毒副反应。结果 60例患者均可评价疗效,卡培他滨组的RR(66.7%vs.46.7%,P<0.05)和DCR(96.7%vs.83.3%,P<0.05)均高于表柔比星组,中位PFS长于表柔比星组(11.7个月vs.8.5个月,P<0.05);两组的毒副反应主要以骨髓抑制、胃肠道反应、脱发和手足综合征为主,卡培他滨组的手足综合征、血小板减少、脱发的发生率高于表柔比星组(P<0.05)。结论卡培他滨在多西紫杉醇一线治疗转移性乳腺癌的效果较好,毒副反应低,可在临床治疗中进行推广。
Objective To investigate the effect of capecitabine and epirubicin in the treatment of metastatic breast cancer in the first line of docetaxel. Methods 60 patients with metastatic breast cancer were randomly divided into capecitabine group and epirubicin group. Both groups were given docetaxel first-line treatment (75 mg/m 2 intravenous infusion, 1 d), and given to cardi He was on the side (2 000 mg/m 2 per day, administered orally twice, on the 1st to 14th day) and epirubicin (75 mg/m 2 iv on the 1st day), 21d for 1 cycle. The short-term efficacy (median progression-free survival PFS) and toxicities during treatment were analyzed for the short-term efficacy (total effective rate RR, disease-recovery rate DCR) of the two groups. Results The efficacy was evaluated in all 60 patients. RR (66.7% vs. 46.7%, P<0.05) and DCR (96.7% vs. 83.3%, P<0.05) were higher in the capecitabine group than in the epirubicin group. The median PFS was longer in the epirubicin group (11.7 months vs. 8.5 months, P<0.05); the toxicity of the two groups mainly consisted of myelosuppression, gastrointestinal reactions, alopecia, and hand-foot syndrome. The incidence of hand-foot syndrome, thrombocytopenia, and alopecia in the peti- terabine group was higher than that in the epirubicin group (P < 0.05). Conclusions Capecitabine is effective in the treatment of metastatic breast cancer in the first-line docetaxel, with low toxic and side effects, and can be promoted in clinical treatment.